Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Biomea Fusion Management

Management Kriterienprüfungen 3/4

Biomea Fusion's CEO ist Thomas Butler, ernannt in Aug 2017, hat eine Amtszeit von 6.75 Jahren. Die jährliche Gesamtvergütung beträgt $2.71M, bestehend aus 22.5% Gehalt und 77.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.94% der Aktien des Unternehmens, im Wert von $27.43M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.1 Jahre bzw. 2.9 Jahre.

Wichtige Informationen

Thomas Butler

Geschäftsführender

US$2.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	22.5%
Amtszeit als Geschäftsführer	6.8yrs
Eigentum des Geschäftsführers	6.9%
Durchschnittliche Amtszeit des Managements	3.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

Aug 01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Jul 20

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Mar 16

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Nov 27

Biomea Fusion: Patience Warranted

Sep 23

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Thomas Butler im Vergleich zu den Einnahmen von Biomea Fusion verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$127m
Dec 31 2023	US$3m	US$609k	-US$117m
Sep 30 2023	n/a	n/a	-US$108m
Jun 30 2023	n/a	n/a	-US$102m
Mar 31 2023	n/a	n/a	-US$95m
Dec 31 2022	US$921k	US$583k	-US$82m
Sep 30 2022	n/a	n/a	-US$71m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$7m	US$552k	-US$42m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$2m	US$229k	-US$5m

Vergütung im Vergleich zum Markt: ThomasDie Gesamtvergütung ($USD2.71M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD2.49M).

Entschädigung vs. Einkommen: ThomasDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Thomas Butler (43 yo)

6.8yrs

Amtszeit

US$2,707,310

Vergütung

Mr. Thomas Butler co-founded Biomea Fusion, Inc in August 2017 and has been its Chief Executive Officer and Director since August 2017. He serves as the Chairman of Biomea Fusion, Inc. He serves as a Manag...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Thomas Butler	Co-Founder	6.8yrs	US$2.71m	6.94% $ 28.1m
Ramses Erdtmann	Co-Founder	6.8yrs	keine Daten	5.71% $ 23.1m
Franco Valle	CFO & Principal Accounting Officer	2.9yrs	US$1.30m	0.071% $ 287.9k
Juan Frias	Chief Medical Officer	less than a year	US$4.17m	0% $ 0
Heow Tan	Chief Technology & Quality Officer	3.6yrs	keine Daten	keine Daten
Naomi Cretcher	Chief People Officer	no data	keine Daten	keine Daten
Thorsten Kirschberg	Executive Vice President of Chemistry	3.8yrs	keine Daten	keine Daten
Stephan Morris	Chief Development Officer	2.3yrs	keine Daten	keine Daten
Ravi Upasani	Executive Vice President of Intellectual Property	3.2yrs	keine Daten	keine Daten
Caroline Perez- Dupont	Senior Vice President of Contracts	less than a year	keine Daten	keine Daten

3.2yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: BMEADas Führungsteam des Unternehmens gilt als erfahren (3.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Thomas Butler	Co-Founder	6.8yrs	US$2.71m	6.94% $ 28.1m
Ramses Erdtmann	Co-Founder	6.8yrs	keine Daten	5.71% $ 23.1m
Eric Aguiar	Independent Lead Director	3.5yrs	US$254.80k	0% $ 0
Elizabeth Faust	Independent Director	2yrs	US$221.99k	0% $ 0
Bihua Chen	Independent Director	3.5yrs	US$228.80k	0% $ 0
Sumita Ray	Independent Director	3yrs	US$235.30k	0% $ 0
Michael J. Hitchcock	Independent Director	3.3yrs	US$241.30k	0.014% $ 56.3k

3.5yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: BMEADie Vorstandsmitglieder gelten als erfahren (3.4 Jahre durchschnittliche Amtszeit).

Biomea Fusion Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

High number of new and inexperienced directors

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

Recent updates

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target increased by 17% to US$48.63

Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific Sessions

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Price target increased by 24% to US$27.50

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

High number of new and inexperienced directors

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Price target increased to US$23.60

Biomea Fusion, Inc. Announces First Patient Dosed with Chronic Lymphocytic Leukemia (Cll) in Covalent-101 Trial

FDA Clears Biomea's IND Application to Begin A Phase I/Ib Trial of BMF-219

Biomea Fusion Presents New Preclinical Data At the European Association for the Study of Diabetes (Easd) Annual Meeting Describing Bmf-219’S Potential as A Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Growth Index

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc. Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models At Ada 2022

Price target decreased to US$19.50

Biomea Fusion, Inc. Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$21.00

High number of new and inexperienced directors

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

High number of new and inexperienced directors

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Biomea Plans to Initiate Enrollment of Patients with MM and Diffuse Large B-Cell Lymphoma (DLBCL) in the Ongoing Phase I Clinical Trial of BMF-219 in the First Half of 2022

Biomea Fusion, Inc. Appoints Steve Morris, M.D. as Chief Medical Officer

Biomea Fusion, Inc. Announces First Patient Dosed

CFO & Principal Accounting Officer recently bought US$87k worth of stock

Biomea Fusion, Inc. Announces 2022 Clinical Development Plan to Initiate Studies in Up to Seven Different Tumor Types and in Diabetes for BMF-219

Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

High number of new directors

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Biomea Fusion: Patience Warranted

Executive Officer Sunny Ryan has left the company

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung